Julie V. Early

733 total citations
27 papers, 534 citations indexed

About

Julie V. Early is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Julie V. Early has authored 27 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 15 papers in Epidemiology and 11 papers in Molecular Biology. Recurrent topics in Julie V. Early's work include Tuberculosis Research and Epidemiology (19 papers), Mycobacterium research and diagnosis (15 papers) and Cancer therapeutics and mechanisms (8 papers). Julie V. Early is often cited by papers focused on Tuberculosis Research and Epidemiology (19 papers), Mycobacterium research and diagnosis (15 papers) and Cancer therapeutics and mechanisms (8 papers). Julie V. Early collaborates with scholars based in United States, India and United Kingdom. Julie V. Early's co-authors include Tanya Parish, Luiz E. Bermudez, Torey Alling, Edison S. Zuniga, Kay A. Fischer, Philip A. Hipskind, Mai A. Bailey, Thierry Masquelin, Joshua Odingo and Anuradha Kumar and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Medicinal Chemistry.

In The Last Decade

Julie V. Early

27 papers receiving 520 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie V. Early United States 14 289 217 210 173 50 27 534
Manju Yasoda Krishnan India 13 250 0.9× 212 1.0× 197 0.9× 58 0.3× 44 0.9× 25 434
Thulasi Warrier United States 15 335 1.2× 257 1.2× 284 1.4× 137 0.8× 97 1.9× 24 647
Zuzana Svetlíková Slovakia 8 219 0.8× 136 0.6× 316 1.5× 116 0.7× 31 0.6× 9 464
Katherine A. Abrahams United Kingdom 12 393 1.4× 233 1.1× 410 2.0× 113 0.7× 77 1.5× 17 629
Andréanne Lupien Canada 14 280 1.0× 216 1.0× 273 1.3× 84 0.5× 123 2.5× 20 534
Md. Mahmudul Islam Bangladesh 15 307 1.1× 220 1.0× 279 1.3× 79 0.5× 48 1.0× 47 680
Sarah E. M. Born United States 5 367 1.3× 272 1.3× 277 1.3× 62 0.4× 78 1.6× 7 516
Chiranjibi Chhotaray China 11 280 1.0× 194 0.9× 174 0.8× 74 0.4× 42 0.8× 14 399
Gaëlle S. Kolly Switzerland 9 324 1.1× 190 0.9× 315 1.5× 77 0.4× 31 0.6× 11 483
Stefanie Boy‐Röttger Switzerland 6 313 1.1× 205 0.9× 196 0.9× 43 0.2× 84 1.7× 6 410

Countries citing papers authored by Julie V. Early

Since Specialization
Citations

This map shows the geographic impact of Julie V. Early's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie V. Early with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie V. Early more than expected).

Fields of papers citing papers by Julie V. Early

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie V. Early. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie V. Early. The network helps show where Julie V. Early may publish in the future.

Co-authorship network of co-authors of Julie V. Early

This figure shows the co-authorship network connecting the top 25 collaborators of Julie V. Early. A scholar is included among the top collaborators of Julie V. Early based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie V. Early. Julie V. Early is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kumar, Anuradha, Somsundaram Chettiar, Brian S. Brown, et al.. (2022). Novel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening. Scientific Reports. 12(1). 14879–14879. 5 indexed citations
2.
Shelton, Catherine, Matthew B. McNeil, Julie V. Early, Thomas R. Ioerger, & Tanya Parish. (2021). Deletion of Rv2571c Confers Resistance to Arylamide Compounds in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 65(5). 2 indexed citations
3.
Hembre, Erik J., Julie V. Early, Joshua Odingo, et al.. (2021). Novel Trifluoromethyl Pyrimidinone Compounds With Activity Against Mycobacterium tuberculosis. Frontiers in Chemistry. 9. 613349–613349. 1 indexed citations
4.
Early, Julie V., Steven F. Mullen, & Tanya Parish. (2019). A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis. PLoS ONE. 14(10). e0222970–e0222970. 19 indexed citations
5.
McGuffin, Sarah, Steven F. Mullen, Julie V. Early, & Tanya Parish. (2019). 1341. Development of a Series of High-Throughput Screens to Identify Leads for Nontuberculous Mycobacteria Drug Design. Open Forum Infectious Diseases. 6(Supplement_2). S485–S485. 1 indexed citations
6.
Early, Julie V., et al.. (2019). Anthranilic amide and imidazobenzothiadiazole compounds disruptMycobacterium tuberculosismembrane potential. MedChemComm. 10(6). 934–945. 7 indexed citations
7.
Barman, Soma, et al.. (2019). The relevance of persisters in tuberculosis drug discovery. Microbiology. 165(5). 492–499. 37 indexed citations
8.
Odingo, Joshua, Julie V. Early, Mai A. Bailey, et al.. (2019). 8‐Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis. Drug Development Research. 80(5). 566–572. 18 indexed citations
9.
MARTINEZ‐GRAU, A., Julie V. Early, Aaron Korkegian, et al.. (2018). Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters. 28(10). 1758–1764. 10 indexed citations
10.
Early, Julie V., Juliane Ollinger, Crystal M. Darby, et al.. (2018). Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis. ACS Infectious Diseases. 5(2). 272–280. 25 indexed citations
11.
Odingo, Joshua, Mai A. Bailey, Megan Files, et al.. (2017). In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis. ACS Omega. 2(9). 5873–5890. 20 indexed citations
12.
Kesicki, Edward A., Mai A. Bailey, Yulia Ovechkina, et al.. (2016). Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents. PLoS ONE. 11(5). e0155209–e0155209. 50 indexed citations
13.
Early, Julie V., et al.. (2016). Mycobacterium tuberculosis Rv0560c is not essential for growth in vitro or in macrophages. Tuberculosis. 102. 3–7. 5 indexed citations
14.
Alling, Torey, Mai A. Bailey, Megan Files, et al.. (2015). Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity. Journal of Medicinal Chemistry. 58(18). 7273–7285. 34 indexed citations
15.
Early, Julie V. & Torey Alling. (2015). Determination of Compound Kill Kinetics Against Mycobacterium tuberculosis. Methods in molecular biology. 1285. 269–279. 10 indexed citations
16.
Odingo, Joshua, Theresa O’Malley, Edward A. Kesicki, et al.. (2014). Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents. Bioorganic & Medicinal Chemistry. 22(24). 6965–6979. 26 indexed citations
17.
O’Malley, Theresa, Edward A. Kesicki, Torey Alling, et al.. (2014). Bioorganic & Medicinal Chemistry 22 (2014) 6965–6979. 24 indexed citations
18.
Early, Julie V., Kay A. Fischer, & Luiz E. Bermudez. (2010). Mycobacterium avium uses apoptotic macrophages as tools for spreading. Microbial Pathogenesis. 50(2). 132–139. 59 indexed citations
19.
Bermudez, Luiz E., Julie V. Early, & Lia Danelishvili. (2006). Mycobacteria and Macrophage Apoptosis: Complex Struggle for Survival. Microbe Magazine. 1(8). 372–375. 9 indexed citations
20.
Martin, Helmut, Julie V. Early, & J E Bridger. (1979). The isolation of herpesvirus from psittacine birds. Veterinary Record. 105(11). 256–258. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manju Yasoda Krishnan Breakdown of academic impact, for papers by Thulasi Warrier Breakdown of academic impact, for papers by Zuzana Svetlíková Breakdown of academic impact, for papers by Katherine A. Abrahams Breakdown of academic impact, for papers by Andréanne Lupien Breakdown of academic impact, for papers by Md. Mahmudul Islam Breakdown of academic impact, for papers by Sarah E. M. Born Breakdown of academic impact, for papers by Chiranjibi Chhotaray Breakdown of academic impact, for papers by Gaëlle S. Kolly Breakdown of academic impact, for papers by Stefanie Boy‐Röttger
Rankless by CCL
2026